BioCentury
ARTICLE | Clinical News

CymaBay falls on Phase IIb gout data

February 25, 2015 3:03 AM UTC

CymaBay Therapeutics Inc. (NASDAQ:CBAY) fell $2.27 (19%) to $9.98 on Tuesday after reporting interim data from its Phase IIb trial of arhalofenate ( MBX-102) to treat gout.

While the trial met its primary endpoint -- with those receiving 800 mg of the oral uricosuric acid demonstrating a 46% reduction in gout flare rate vs. 300 mg of allopurinol after 12 weeks (p=0.0056) -- CymaBay said neither a 600 mg nor 800 mg dose of arhalofenate led to a statistically significant number of patients reaching the goal of <6 mg/dL reduction in serum uric acid (sUA), a level associated with reduced risk of gout flares. The trial included gout patients with hyperuricemia who had experienced three or more flares in the previous 12 months. ...